

Semaglutide for Type 2 Diabetes

NHS Devon

Commissioning policy

The routine commissioning of semaglutide is accepted in Devon for patients with type 2 diabetes as described for GLP-1 mimetics in National Institute for Health and Care Excellence (NICE) guideline NG28. The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise.

Evidence from clinical trials demonstrates that semaglutide is more efficacious than other locally commissioned GLP-1 receptor agonists, producing greater clinically significant reduction in both HbA1c and bodyweight. NICE defines the place in treatment intensification for this class of drug in NG28.

The annual acquisition cost for semaglutide is the same as, or less, than the majority of other GLP-1 receptor agonists and it is considered good value for money.

Guidance notes on exceptionality

This general policy does not replace clinical judgement on the appropriate treatment of an individual patient.

Date of publication:	Version:
28.05.2019	Policy agreed by NHS Devon CCG
	Policy adopted by NHS Devon ICB on 01.07.2022
	Reviewed 17.04.2024